Laminin activates the p185HER2 oncprotein and mediates growth inhibition of breast carcinoma cells

E Tagliaabue,1 E Ardini1, R Pellegrini1, M Campiglio1, R Bufalino2, M Jeschke3, B Groner4, MI Colnaghi1 and S Ménard1

1Division of Experimental Oncology E, 2Statistical Analysis and Informatic Laboratory of PRESTCO, Istituto Nazionale Tumori, 20133 Milan, Italy; 3Friedrich Miescher-Institute Basle, Switzerland; 4Tumor Biology Center, Freiburg im Breisgau, Germany.

Summary The interaction between laminin and the oncprotein encoded by the c-erbB-2 oncogene was studied in vitro and in vivo in human breast carcinomas. In vitro analysis of breast carcinoma cell lines overexpressing p185HER2 revealed that laminin, but not fibronectin, induced tyrosine phosphorylation and down-modulation of oncprotein membrane expression. Laminin also specifically inhibited growth of p185HER2 positive cell lines. No direct binding between the recombinant extracellular domain of p185HER2 and laminin was found. Induction of oncprotein down-modulation by anti-integrin antibodies and coprecipitation of the oncprotein with the β4 integrin subunit indicate that the interaction between p185HER2 and laminin occurs through integrin molecules. The relevance of the in vitro observations was verified in vivo by analysing the prognostic value of p185HER2 overexpression as a function of laminin production on archival paraffin-embedded sections of 887 primary breast tumours. The results revealed an association between p185HER2 overexpression and unfavourable prognosis in tumours negative for laminin production, whereas in laminin-producing tumours, the oncprotein overexpression was not associated with tumour aggressiveness.

Keywords: laminin; oncprotein; breast cancer

The c-erbB-2 proto-oncogene encodes a transmembrane glycoprotein of 185 kDa (p185HER2) with intrinsic tyrosine kinase activity and close homology with the epidermal growth factor (EGF) receptor (Coussens et al., 1985). Amplification of the c-erbB-2 gene and overexpression of its product induce cell transformation (Di Fiore et al., 1987) and have been associated with poor prognosis in different tumours of epithelial origin (Rilke et al., 1991; Berchuck et al., 1990; Kern et al., 1990; Gullick, 1990; Slamon et al., 1989). Monoclonal antibodies (M Abs) directed to p185HER2 (Hurwitz et al., 1995; Stancovski et al., 1991; Tagliabue et al., 1991; Hudziak et al., 1989; McKenzie et al., 1989), as well as different candidate ligands of the p185HER2 receptor (Samanta et al., 1994; Huang et al., 1992; Wen et al., 1992; Holmes et al., 1992; Peles et al., 1992; Djabali et al., 1991, Tarakhovsky et al., 1991; Luptu et al., 1990; Yarden et al., 1989) and oestrogen (Matsuda et al., 1993), have been shown either to stimulate or to inhibit cell growth. c-erbB-2 can also be activated by interaction with other activated members of the EGF receptor family. Ligand-dependent activation of the EGFR, c-erbB-3 or c-erbB-4 by EGF or heregulin/neu-differentiating factor (HRG/NDF) have been shown to result in heterodimerisation and, thereby, activation of c-erbB-2 (Tzahar et al., 1994; Kita et al., 1994; Carraway et al., 1994; Plowman et al., 1993b; Connelly et al., 1990). In some cell lines, HRG/NDF can also induce differentiation (Peles et al., 1992; Bacus et al., 1992).

We have recently shown (Campiglio et al., 1994) that α6β4 integrin capping, induced by anti-integrin M Abs, also gives rise to p185HER2 clustering and tyrosine phosphorylation of this receptor. Laminin, the ligand of the α6β4 receptor (Lee et al., 1992), increases the basal level of p185HER2 phosphorylation (Campiglio et al., 1994), suggesting a role for adhesion molecules in the activation of the oncprotein.

In the present study, we investigated the effects of soluble laminin on p185HER2 activation and expression in breast carcinoma cell lines overexpressing the oncprotein. To verify the relevance of the in vitro observations on in vivo tumour aggressiveness, we also evaluated the prognostic value of c-erbB-2 overexpression relative to laminin production in a series of 887 primary breast carcinomas.

Materials and methods

Cells and culture conditions

Human breast carcinoma cell lines SKBr3, MDA MB453 and MCF-7 (ATCC, Rockville, MD, USA) were maintained in RPMI-1640 (Sigma Chemical Co., St Louis, MO, USA) with 5% fetal calf serum (FCS) supplemented with penicillin (100 mg ml⁻¹) and streptomycin (100 mg ml⁻¹). For the proliferation assay, cells were seeded at a density of 250 x 10³ per well in triplicate 6-well plates in the presence or absence of exogenously added adhesion molecules (50 µg ml⁻¹). After 4 days, cells were trypsinised and counted under the light microscope. Murine laminin, purified from mouse Engelbreth Holm Swurm tumour cells, and human fibronectin, purified from plasma, were obtained from Sigma and Boehringer Mannheim (Germany) respectively.

Flow cytometric analysis

Antigens expressed by laminin-treated cells were quantitated by indirect immunofluorescence with fluorescein isothiocyanate-conjugated goat anti-mouse Ig (Kirkegaard and Perry Laboratories Inc., Gaithersburg, MD, USA) and the following purified M Abs: MGR2, directed against the extracellular domain of p185HER2 (Tagliaabue et al., 1991); MGR1, directed against the extracellular domain of the EGF receptor (Pellegrini et al., 1991); and W6/32, directed against a monomorphic determinant of human HLA-A,B,C molecules (Parham et al., 1979). Fluorescence intensity was measured using a FACScan flow cytometer with LYSIS II software (Becton Dickinson, Mountain View, CA, USA).

Analysis of oncprotein tyrosine phosphorylation

Breast carcinoma cells treated with laminin for 5 min were lysed using non-ionic detergent (1% NP40 in 50 mM Tris-
Laminin and p185HER2
E Tagliabue et al

HCl, pH 7.4) in the presence of phosphatase inhibitors (1 mM sodium orthovanadate) and 2 mg of lyase was immunoprecipitated with MAb MGR2. Immunoprecipitates were subjected to immunoblot analysis with anti-P-Tyr MAb (4 µg ml⁻¹) (Upstate Biotechnology, Inc., Lake Placid, NY, USA) and with MAb c-neu Ab3 (1 µg ml⁻¹), which specifically detects the p185HER2 carboxy-terminal peptide (Oncogene Science, Inc. Manhasset, NY, USA).

Extracellular domain (ECD) treatment
The human c-erbB-2 receptor extracellular domain (ECD) was produced using the baculovirus expression system (Luckow et al., 1989). A 2 kb cDNA encoding amino acids 1 to 622 of the erbB-2 protein (Akiyama et al., 1986) was cloned into the expression transfer vector pVL1393 using Smal and XbaI cloning sites. Stop codons were inserted at the 3' end of the ECD coding sequence. The protein was expressed in Sf9 cells and purified from the culture medium 4 days after infection with the recombinant virus. Recombinant protein (20 µg) purified by immunoaffinity chromatography was labelled with ¹²⁵I by the Bolton–Hunter reagent (Amersham, Little Chalfont, UK). The functionality and specificity of the labelled molecule were assessed in a binding assay using polystyrene beads coated with MAbS MGR2 and MGR4 against the oncoprotein ECD (Centis et al., 1992; Tagliabue et al., 1991), or with an unrelated MAb (Martignone et al., 1992). Binding of labelled ECD was assayed in wells of 96-well plates adsorbed with laminin, fibronectin, bovine serum albumin (BSA) or MAb MGR2 at a concentration of 10 µg per well.

Co-immunoprecipitation
MDA MB453 breast carcinoma cells were treated with laminin (50 µg ml⁻¹) for 5 min and lysed in the absence of ionic detergent. Lysate (2 mg) was immunoprecipitated with the following MAbS: MAR4 directed against the β1 integrin subunit (Pellegrini et al., 1992); and 3E1 directed against the β4 integrin subunit (Telios, San Diego, CA, USA). Immunoprecipitates were subjected to immunoblot analysis with MAb c-neu Ab3 (Oncogene Science), and the proteins were visualised with the ECL detection system (Amersham). Filters were stripped in a buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% sodium dodecyl sulphate (SDS) and 100 mM β-mercaptoethanol for 30 min at 65°C and reprobed with the indicated antibodies.

Surgical specimens
Paraffin-embedded tissues obtained surgically from 887 patients with breast cancer and collected in our Institute from January 1968 to December 1971 were examined. In patients with histologically positive axillary lymph nodes, surgery was combined with subsequent radiotherapy on supraclavicular and internal mammary lymph nodes. No systemic treatment was administered until the time of relapse.

Immunohistochemical analysis
Rabbit polyclonal antibodies directed against p185HER2 (kindly provided by Dr DJ Slamon, UCLA School of Medicine, Los Angeles, CA, USA) (1:500), and rabbit antisera directed against human laminin (Telios, San Diego, CA, USA) (1:100) were used. The immunoperoxidase test was carried out on paraffin-embedded sections using the avidin–biotin–peroxidase complex (ABC) kit (Vector, Burlingame, CA, USA).

Statistical analysis
Overall survival of patients from the date of surgery was evaluated, considering only deaths from breast cancer as events. Survival rates were evaluated using the actuarial life-table approach. The log-rank method was used to analyse the differences in survival curves.

Results
In vitro analysis of p185HER2 and laminin interaction
Three cell lines, two overexpressing c-erbB-2 (SKBr3 and MDA MB453) and one not expressing the oncogene (MCF-7), were cultured in the presence of laminin or fibronectin for 4 days and tested for expression and activation of the c-erbB-2 oncoprotein. Laminin induced a down-modulation of the membrane expression of the oncoprotein as compared with untreated or fibroinectin-treated cells on the two cell lines overexpressing p185HER2, whereas no change was found for MCF-7 cells, which do not express this oncoprotein (Figure 1).

Figure 1 Cytofluorimetric analysis of p185HER2 expression in SKBr3 (a and b), MDA MB453 (c and d) and MCF-7 cells (e and f) incubated with (bold line) or without (light line) laminin (a, c and e) or fibronectin (b, d, and f). Dotted lines show background values.

Table I Effect of laminin on membrane marker expression in breast carcinoma cells

| Cell line | Treatment with laminin | p185HER2 Marker fluorescence intensity a | EGFR Marker fluorescence intensity a | HLA |
|-----------|------------------------|----------------------------------------|---------------------------------|------|
|           |                        | p185HER2                               | EGFR                            |      |
| SKBr3     |                        | 524 ± 164                              | 98 ± 20 ≤ 5                    |      |
|           | +                      | 96 ± 30 b                               | 96 ± 15 ≤ 5                    |      |
| MDA MB 453|                        | 326 ± 114                              | 42 ± 13 ≤ 10                    |      |
|           | +                      | 130 ± 52 b                              | 45 ± 10 ≤ 5                    |      |
| MCF-7     |                        | 29 ± 8                                 | 21 ± 5 ≤ 5                     |      |
|           | +                      | 27 ± 5                                 | 23 ± 7 ≤ 5                     | 108 ± 19 |

aMean fluorescence intensity ± s.d. obtained from five experiments by immunofluorescence assay and FACSscan analysis. Statistically significant decrease determined using Student's t-test.
This down-modulation induced by laminin was reproducible and significant, whereas no effect on EGFR and class I HLA expression was observed (Table 1). Time course analysis of p185HER2 down-modulation revealed decreased oncoprotein expression on the cell surface of p185HER2, overexpressing cell lines after 1 h of laminin treatment, with further down-modulation until 4 days, when decreased p185HER2 expression plateaued (Figure 2).

To determine whether the rapid membrane down-modulation of oncoprotein was associated with activation of p185HER2, the state of receptor tyrosine phosphorylation was determined in the same cell lines treated or not with soluble laminin. As detected by immunoblot analysis of anti-p185HER2 immunoprecipitates with anti-P-Tyr antibodies, tyrosine phosphorylation of oncoprotein was increased in SKBr3 cells after treatment with soluble laminin (Figure 3). A smaller, but still significant, increase was observed in MDA MB453 cells after the same treatment (data not shown).

Proliferation assay of different breast carcinoma cells grown in the presence of 50 μg ml⁻¹ laminin or fibronectin for 4 days indicated that laminin, but not fibronectin, induces a 40% inhibition of cell growth in both cell lines overexpressing p185HER2 (SKBr3 and MDA MB453), whereas no variation was found for MCF-7 cells (Figure 4).

Analysis to determine whether the two molecules interact directly indicated no binding of radiolabelled p185HER2 ECD to laminin or to fibronectin and BSA used as negative controls, whereas the same labelled molecule was recognised by a MAb directed against the p185HER2 ECD (Figure 5).

Based on the observed colocalisation of p185HER2 and the α6β4 integrin receptor in a lung carcinoma cell line (Campiglio et al., 1994), the possibility of an indirect interaction mediated by this integrin receptor was investigated. The down-modulation of oncoprotein membrane expression was analysed in SKBr3 and MDA MB453 cells after treatment with MAb GoH3 (Immunotech, Inc.,

![Figure 2](image2.png) Cytofluorimetric analysis of p185HER2 down-modulation as a function of duration of laminin treatment of SKBr3 ( ), MDA MB453 ( ) and MCF-7 ( ) cells.

![Figure 4](image4.png) Effect of laminin (a) or fibronectin (b) on breast carcinoma cell proliferation. Proliferation in medium alone ( ) or in medium containing exogenous adhesion molecules ( ). Values are the mean ± s.d. of three separate experiments.

![Figure 3](image3.png) Tyrosine phosphorylation of p185HER2 as a function of laminin treatment. Immunoblot with anti-P-Tyr and c-neu Ab3 Mabs of anti-p185HER2 immunoprecipitates from SKBr3 cells incubated with or without laminin.

![Figure 5](image5.png) Binding of labelled extracellular domain (ECD) of p185HER2 to laminin ( ), fibronectin ( ), BSA ( ) or MAb MGR2 ( ).
Laminin and p185HER2
E Tagliabue et al

Westbrook, ME, USA), which is directed against the laminin binding site of the α6 integrin subunit. Laminin and the anti-α6 MAb each induced a significant \( P < 0.05 \) decrease in p185HER2 membrane expression, and no further down-modulation was observed when cells previously treated with GoH3 were seeded in the presence of laminin (Table II).

To investigate the mechanism of interaction between laminin and p185HER2 further, fresh lysates, obtained from MDA MB453 cells treated with laminin or untreated, were subjected to immunoprecipitation with MAb to β1 and β4 integrin subunits and immunoblotted with an anti-p185HER2 MAb. As shown in Figure 6, the oncprotein was recovered from β4 immunoprecipitates and the amount of coprecipitated p185HER2 was slightly increased in cells treated with laminin. No oncprotein was detectable in the material immunoprecipitated with β1 antibodies.

In vivo analysis of prognostic value of p185HER2

Immunohistochemical analysis of archival paraffin-embedded sections of 887 primary breast carcinomas indicated p185HER2 overexpression and laminin production in 22% and 27% of

| Table II | Expression of p185HER2 in breast cancer cell lines treated with MAb GoH3, laminin or both |
|-----------|------------------------------------------------------------------------------------------------|
| Cell line | Treatment | Fluorescence intensity\(^a\) |
|-----------|-----------|-----------------------------|
| SKBr3     | -         | 570 ± 102                   |
|           | GoH3      | 266 ± 33\(^b\)             |
|           | LN        | 130 ± 42\(^b\)             |
|           | GoH3 + LN | 142 ± 35\(^b\)             |
| MDA MB453 | -         | 350 ± 91                    |
|           | GoH3      | 190 ± 42\(^b\)             |
|           | LN        | 135 ± 27\(^b\)             |
|           | GoH3 + LN | 119 ± 50\(^b\)             |

\(^a\)Mean fluorescence intensity ± s.d. obtained from three experiments by immunofluorescence assay and FACSscan analysis. \(^b\)Statistically significant \( P < 0.05 \) as determined using Student’s t-test.

Figure 6 Western blot analysis of anti-β1 and anti-β4 immunoprecipitates from MDA MB453 cells incubated with or without laminin using c-neu Ab3 MAb. Filters were stripped and reprobed with anti-β1- or anti-β4-specific antibodies.

Figure 7 Immunohistochemical analysis performed on paraffin-embedded sections of breast carcinoma with polyclonal serum against p185HER2 (a) or against laminin (b), or negative control serum (c).

Figure 8 Survival rates of patients with primary breast carcinomas according to p185HER2 overexpression and laminin production. This includes 176 p185HER2-negative, laminin-positive cases (A), 68 p185HER2-positive, laminin-positive cases (V), 514 p185HER2-negative, laminin-negative cases (■), 129 p185HER2-positive, laminin-negative cases (○).
the cases respectively. All of the 197 cases that overexpressed p185HER2 showed a characteristic staining at the cell membrane level (Figure 7a). Tumours were considered laminin positive (244 cases) when they displayed staining at the membrane and/or cytoplasmic level (Figure 7b). Laminin production by itself was not found to be associated with any other prognostic factors, such as nodal status, tumour size and grading (Pellegrini et al., 1995). Survival curves showed a strong correlation between poor prognosis and p185HER2 overexpression (P < 0.01), whereas laminin production per se had no impact on survival. However, when these two parameters were analysed together, the prognostic value of the oncoprotein was significantly influenced by laminin production (Figure 8). For patients with laminin-negative tumours (643 cases), p185HER2 overexpression was significantly associated with poor prognosis (P < 0.01). By contrast, no statistically significant differences in survival rate as a function of p185HER2 overexpression were found in patients with laminin-producing tumours (244 cases).

Discussion

The present study shows that laminin, a molecule of the extracellular matrix, can functionally interact with the c-erbB-2 oncoprotein. In vitro laminin treatment of breast carcinoma cells overexpressing p185HER2 resulted in activation of the oncoprotein as measured by tyrosine phosphorylation, down-modulation of membrane expression and, ultimately, inhibition of cell proliferation. The survival data for breast cancer patients clearly indicate the relevance of this interaction in the proliferation of in vivo human tumours, since p185HER2 overexpression, which is strongly associated with poor prognosis in laminin-negative tumours, almost completely lost its prognostic significance in laminin-producing tumours.

No direct binding between laminin and the c-erbB-2 oncoprotein was detected, suggesting that their interaction is mediated by other molecules. Indeed, the decrease in p185HER2 membrane expression upon treatment with an anti-a6 MAb strongly suggests that the interaction is mediated through laminin-specific integrins. Consistent with this suggestion, coprecipitation of c-erbB-2 with the β4 subunit demonstrates that these molecules are structurally associated on the cell membrane, and their association is increased and stabilised by laminin binding. The interaction appears to be restricted to the β4 integrin, since no oncoprotein was found associated with the β1 integrin. The interaction of laminin integrins induces receptor clustering at the plasma membrane and consequent activation of p185HER2. Up-regulation of membrane protein tyrosine phosphorylation by integrin clustering has been reported (Kornberg et al., 1991), and our recent study in which clustering of the α6β4 integrin receptor in a lung carcinoma cell line was shown to enhance tyrosine phosphorylation of overexpressed p185HER2 (Campiglia et al., 1994) indicates an activation of this oncoprotein in the presence of laminin. Overexpression of p185HER2 at the tumour cell surface is generally thought to lead to a growth-promoting signal (Di Fiore et al., 1987), and p185HER2 uses a signal transduction pathway that is localised at the plasma membrane level (Aronheim et al., 1994; Ben-Leyvet et al., 1994). The laminin-induced removal of p185HER2 from the cell surface may result in decreased growth of those tumour cells that overexpress this receptor. Consistent with the hypothesis that the oncogenic potential of p185HER2 is restricted to the membrane form, antibody-mediated internalisation of this receptor was associated with inhibition of tumour growth (Hurwit et al., 1995). Moreover, a cytoplasmic localisation of c-erbB-2 in breast carcinomas has been linked to better prognosis compared with tumours that showed cell membrane localisation of this receptor (Zschieche et al., 1994).

However, the possibility remains that laminin, upon interacting with integrins, becomes available for binding to other molecules of the HER family that are normally not involved in such a phenomenon owing to insufficient binding affinity. Indeed, heregulin, the ligand for c-erbB-3 and c-erbB-4 (Tzahar et al., 1994; Slwikowski et al., 1994; Plowman et al., 1993b), presents a family of molecules sharing an EGF-like domain, which appears to be responsible for receptor recognition (Panayotou et al., 1989; Holmes et al., 1992; Wen et al., 1992). Similar EGF-like domains are also present in the short arms of laminin (Sasaki et al., 1987; Sasaki and Yamada, 1987). Assuming that EGF-like regions in different proteins are an essential motif for protein–protein interaction, the corresponding domain of laminin might be responsible for the interaction of this adhesion molecule with members of the HER receptor family. In fact, the interaction only with integrins does not explain the differences between SKBr3 and MDA MB453 cells in level of activation, since the latter, which are less responsive to laminin, actually express a higher amount of α6β4 integrin than do SKBr3 cells, but show a different pattern of HER family molecules (Plowman et al., 1993a; Kraus et al., 1993; King et al., 1988).

No morphological evidence of cell differentiation, which has been reported to occur when p185HER2 activation leads to cell growth inhibition (Pele et al., 1992; Bacus et al., 1992), was observed after laminin treatment of cells. However, SKBr3 and MDA MB453 cells have a high level of aneuploidy, which might prevent a clear response to differentiation stimuli. Although the interaction between laminin and p185HER2 occurs by an indirect mechanism, the in vitro and in vivo data demonstrate the importance of this interaction for tumour progression. These data may open new approaches to therapeutic intervention of breast carcinoma that exploit the ability of laminin to reduce p185HER2-related tumour aggressiveness. For this, agents that up-regulate laminin production by the tumour or laminin-derived peptides might be suitable.

Acknowledgements

We thank Mrs Cristina Ghirelli and Mrs Piera Aiello for excellent technical assistance, Mrs Laura Manelli for the preparation of the manuscript, and Mr Mario Azzini for photographic reproduction. This work was partially supported by a grant from the Associazione Italiana per la Ricerca sul Cancro and by CNR-ACRO.

References

AKIYAMA T, SUDO C, OGAWARA M, TOYOSHIMA K AND YAMAMOTO T. (1986). The product of the c-erb-B-2 gene: a 185 Kd glycoprotein with tyrosine kinase activity. Science, 232, 1644–1646.

ARONHEIM A, ENGELBERG D, LI N, AL-ALAWI N, SCHLESSINGER J AND KARIN M. (1994). Membrane targeting of the nucleotide exchange factor sos is sufficient for activating the ras signaling pathway. Cell, 78, 949–961.

BACUS SS, STANCOVSKI I, HUBERMAN E, CHIN D, HURWITZ E, MILLS GB, ULLRICH A, SELA M AND YARDEN Y. (1992). Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res., 52, 2580–2589.

BEN-LEVY R, PATERSON HF, MARSHALL CJ AND YARDEN Y. (1994). A single autophosphorylation site conveys oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J., 13, 3302–3311.

BERUNCHAK A, KAMELA M, GEORGE M, KYRIACOU A, AL-ALAWI N AND KARIN M. (1993). Membrane targeting of the nucleotide exchange factor sos is sufficient for activating the ras signaling pathway. Cell, 78, 949–961.

BEN-LEVY R, PATERSON HF, MARSHALL CJ AND YARDEN Y. (1994). A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J., 13, 3302–3311.

BERUNCHAK A, KAMELA M, GEORGE M, KYRIACOU A, AL-ALAWI N AND KARIN M. (1993). Membrane targeting of the nucleotide exchange factor sos is sufficient for activating the ras signaling pathway. Cell, 78, 949–961.
MARTIGNONE S, PELLEGRINI R, VILLA E, TANDON NN, MAS-TROIANI A, TAGLIABUE E, MÉNARD S AND COLNAGHI MI, (1992). Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression. Clin. Exp. Metast., 10, 379 – 386.

MATSUJO K, KADOKAWA Y, ICHINO M, AKIYAMA T, TOYOSHI K AND YAMAMOTO T. (1993). 17β-Estradiol mimics ligand activity of the erbB2 protooncogene product. Proc. Natl Acad. Sci. USA, 90, 8080–8083.

MCKENZIE SJ, MARKS PJ, LAM T, MORGAN J, PANICALI DL, TRIMPE KL AND CARNEY WP. (1989). Generation and characterization of monoclonal antibodies specific for the human neu oncoprotein, p185. Oncogene, 4 (10), 538–547.

MAYNETOU G, END P, AUMAÎLLE E, TIMPL R AND ENGEL J. (1989). Domains of laminin with growth-factor activity. Cell, 56, 93–101.

PARHAM P, BARNSTABLE CJ AND BODMER W. (1979). Use of a multidimensional structure to define structures in human breast cancers. Nature (London), 280, 522–527.
TAGLIABUE E, CENTIS F, CAMPILGIO M, MASTROIANNI A, MARTIGNONE S, PELLEGRINI R, CASALINI P, LANZI C, MENARD S AND COLNAGHI MI. (1991). Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/neu gene amplification. Int. J. Cancer, 47, 933–937.

TARAKHOVSKY A, ZAICHUK T, PRASSOLOV V AND BUTENKO ZA. (1991). A 25kDa polypeptide is the ligand for p185neu and is secreted by activated macrophages. Oncogene, 6, 2187–2196.

TZAHAR E, LEVKOWITZ G, KARUNAGARAN D, YI L, PELES E, LAVI S, CHANG D, LIU N, YAYON A, WEN D AND YARDEN Y. (1994). ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/hergulin isoforms. J. Biol. Chem., 269, 25226–25233.

WEN D, PELES E, CUPPLES R, SUGGS SV, BACUS SS, LUO Y, TRAIL G, HU S, SILBIGER SM, BEN LEVY R, KOSKI RA, LU HS AND YARDEN Y. (1992). Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell, 69, 559–572.

YARDEN Y AND WEINBERG RA. (1989). Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proc. Natl Acad. Sci. USA, 86, 3179–3183.

ZSCHIESCHE W, SCHÖNBORN I, MINGUillon C AND SPITZER E. (1994). Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis of primary human breast cancer. Cancer Lett., 81, 89–94.